Non-Hodgkin's lymphoma of the stomach: Treatment outcomes for 57 patients over a 20-year period

Ching Liang Ho, An Tie Hsieh, Ming Shen Dai, Yeu Chin Chen, Woei You Kao, Tsu Yi Chao

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Gastric non-Hodgkin's lymphoma (NHL) is a rare subtype of malignancy, for which no consensus exists about treatment. In this study, the treatment outcomes of gastric NHL in 57 patients were retrospectively evaluated for a period of 20 years at a single institute. Methods: Clinical stages were classified according to the Ann Arbor staging system: 29 patients were stage 1, 17 stage II, two stage III, and nine stage IV. The 46 stage I/II patients received aggressive, multimodal therapy: 24 of these (group A) were treated with surgery-based management, which included surgery alone (n = 6), surgery + chemotherapy (CT; n = 14), surgery + radiotherapy (RT; n = 2), and surgery + CT + RT (n = 2); 22 patients (group B) did not receive surgery, but received CT alone (n = 11), CT + RT (n = 5), or, in patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, an oral anti-Helicobacter pylori regimen (n = 6). The 11 stage III/IV patients received CT and/or RT with regimens similar to those for stage I/II patients. Results: Except for 1 patient with an initial surgical diagnosis, 56 patients underwent gastric endoscopic examination, which proved that 42 had NHL. The rate of diagnostic accuracy by gastroscopy was 75%. After multimodal treatment (n = 46) and a median follow-up of 54 months (range, 1-210 months), the 5-year survival rate was 40.3%. The 5-year survival rates for stage I, II and III/IV patients were 57.2%, 47% and 0%, respectively (p <0.005). Of the 24 surgical patients (group A) who received sequential CT, with or without RT, 12 remained disease-free after a median follow-up of 98 months (range, 1-210 months); three patients died because of postoperative complications. Of the 22 non-surgical patients (group B) who received CT, alone or combined with RT, 14 remained disease-free after a median follow-up of 40 months (range, 4-189 months); 1 patient died because of massive gastric hemorrhage after CT. All stage III and IV patients died after a median survival of 4 months (range, 1-8 months). Conclusion: Clinical stage is the most important factor predicting the long-term survival of patients with gastric NHL. Surgery may still be necessary in cases of failed gastroscopic diagnosis. In early-stage gastric NHL, non-surgical treatment seems able to achieve the aims of improved long-term survival and, in some instances, cure.

Original languageEnglish
Pages (from-to)11-15
Number of pages5
JournalJournal of the Chinese Medical Association
Volume68
Issue number1
Publication statusPublished - Jan 2005
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Stomach
Survival
Survival Rate
Gastroscopy
Combined Modality Therapy
Marginal Zone B-Cell Lymphoma
Group Psychotherapy
Helicobacter pylori
Consensus
Radiotherapy

Keywords

  • Chemotherapy
  • Gastroscopy
  • Non-Hodgkin's lymphoma
  • Radiotherapy
  • Surgery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Non-Hodgkin's lymphoma of the stomach : Treatment outcomes for 57 patients over a 20-year period. / Ho, Ching Liang; Hsieh, An Tie; Dai, Ming Shen; Chen, Yeu Chin; Kao, Woei You; Chao, Tsu Yi.

In: Journal of the Chinese Medical Association, Vol. 68, No. 1, 01.2005, p. 11-15.

Research output: Contribution to journalArticle

Ho, Ching Liang ; Hsieh, An Tie ; Dai, Ming Shen ; Chen, Yeu Chin ; Kao, Woei You ; Chao, Tsu Yi. / Non-Hodgkin's lymphoma of the stomach : Treatment outcomes for 57 patients over a 20-year period. In: Journal of the Chinese Medical Association. 2005 ; Vol. 68, No. 1. pp. 11-15.
@article{ca85f432a052499cac65971881f0b57b,
title = "Non-Hodgkin's lymphoma of the stomach: Treatment outcomes for 57 patients over a 20-year period",
abstract = "Background: Gastric non-Hodgkin's lymphoma (NHL) is a rare subtype of malignancy, for which no consensus exists about treatment. In this study, the treatment outcomes of gastric NHL in 57 patients were retrospectively evaluated for a period of 20 years at a single institute. Methods: Clinical stages were classified according to the Ann Arbor staging system: 29 patients were stage 1, 17 stage II, two stage III, and nine stage IV. The 46 stage I/II patients received aggressive, multimodal therapy: 24 of these (group A) were treated with surgery-based management, which included surgery alone (n = 6), surgery + chemotherapy (CT; n = 14), surgery + radiotherapy (RT; n = 2), and surgery + CT + RT (n = 2); 22 patients (group B) did not receive surgery, but received CT alone (n = 11), CT + RT (n = 5), or, in patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, an oral anti-Helicobacter pylori regimen (n = 6). The 11 stage III/IV patients received CT and/or RT with regimens similar to those for stage I/II patients. Results: Except for 1 patient with an initial surgical diagnosis, 56 patients underwent gastric endoscopic examination, which proved that 42 had NHL. The rate of diagnostic accuracy by gastroscopy was 75{\%}. After multimodal treatment (n = 46) and a median follow-up of 54 months (range, 1-210 months), the 5-year survival rate was 40.3{\%}. The 5-year survival rates for stage I, II and III/IV patients were 57.2{\%}, 47{\%} and 0{\%}, respectively (p <0.005). Of the 24 surgical patients (group A) who received sequential CT, with or without RT, 12 remained disease-free after a median follow-up of 98 months (range, 1-210 months); three patients died because of postoperative complications. Of the 22 non-surgical patients (group B) who received CT, alone or combined with RT, 14 remained disease-free after a median follow-up of 40 months (range, 4-189 months); 1 patient died because of massive gastric hemorrhage after CT. All stage III and IV patients died after a median survival of 4 months (range, 1-8 months). Conclusion: Clinical stage is the most important factor predicting the long-term survival of patients with gastric NHL. Surgery may still be necessary in cases of failed gastroscopic diagnosis. In early-stage gastric NHL, non-surgical treatment seems able to achieve the aims of improved long-term survival and, in some instances, cure.",
keywords = "Chemotherapy, Gastroscopy, Non-Hodgkin's lymphoma, Radiotherapy, Surgery",
author = "Ho, {Ching Liang} and Hsieh, {An Tie} and Dai, {Ming Shen} and Chen, {Yeu Chin} and Kao, {Woei You} and Chao, {Tsu Yi}",
year = "2005",
month = "1",
language = "English",
volume = "68",
pages = "11--15",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "1",

}

TY - JOUR

T1 - Non-Hodgkin's lymphoma of the stomach

T2 - Treatment outcomes for 57 patients over a 20-year period

AU - Ho, Ching Liang

AU - Hsieh, An Tie

AU - Dai, Ming Shen

AU - Chen, Yeu Chin

AU - Kao, Woei You

AU - Chao, Tsu Yi

PY - 2005/1

Y1 - 2005/1

N2 - Background: Gastric non-Hodgkin's lymphoma (NHL) is a rare subtype of malignancy, for which no consensus exists about treatment. In this study, the treatment outcomes of gastric NHL in 57 patients were retrospectively evaluated for a period of 20 years at a single institute. Methods: Clinical stages were classified according to the Ann Arbor staging system: 29 patients were stage 1, 17 stage II, two stage III, and nine stage IV. The 46 stage I/II patients received aggressive, multimodal therapy: 24 of these (group A) were treated with surgery-based management, which included surgery alone (n = 6), surgery + chemotherapy (CT; n = 14), surgery + radiotherapy (RT; n = 2), and surgery + CT + RT (n = 2); 22 patients (group B) did not receive surgery, but received CT alone (n = 11), CT + RT (n = 5), or, in patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, an oral anti-Helicobacter pylori regimen (n = 6). The 11 stage III/IV patients received CT and/or RT with regimens similar to those for stage I/II patients. Results: Except for 1 patient with an initial surgical diagnosis, 56 patients underwent gastric endoscopic examination, which proved that 42 had NHL. The rate of diagnostic accuracy by gastroscopy was 75%. After multimodal treatment (n = 46) and a median follow-up of 54 months (range, 1-210 months), the 5-year survival rate was 40.3%. The 5-year survival rates for stage I, II and III/IV patients were 57.2%, 47% and 0%, respectively (p <0.005). Of the 24 surgical patients (group A) who received sequential CT, with or without RT, 12 remained disease-free after a median follow-up of 98 months (range, 1-210 months); three patients died because of postoperative complications. Of the 22 non-surgical patients (group B) who received CT, alone or combined with RT, 14 remained disease-free after a median follow-up of 40 months (range, 4-189 months); 1 patient died because of massive gastric hemorrhage after CT. All stage III and IV patients died after a median survival of 4 months (range, 1-8 months). Conclusion: Clinical stage is the most important factor predicting the long-term survival of patients with gastric NHL. Surgery may still be necessary in cases of failed gastroscopic diagnosis. In early-stage gastric NHL, non-surgical treatment seems able to achieve the aims of improved long-term survival and, in some instances, cure.

AB - Background: Gastric non-Hodgkin's lymphoma (NHL) is a rare subtype of malignancy, for which no consensus exists about treatment. In this study, the treatment outcomes of gastric NHL in 57 patients were retrospectively evaluated for a period of 20 years at a single institute. Methods: Clinical stages were classified according to the Ann Arbor staging system: 29 patients were stage 1, 17 stage II, two stage III, and nine stage IV. The 46 stage I/II patients received aggressive, multimodal therapy: 24 of these (group A) were treated with surgery-based management, which included surgery alone (n = 6), surgery + chemotherapy (CT; n = 14), surgery + radiotherapy (RT; n = 2), and surgery + CT + RT (n = 2); 22 patients (group B) did not receive surgery, but received CT alone (n = 11), CT + RT (n = 5), or, in patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, an oral anti-Helicobacter pylori regimen (n = 6). The 11 stage III/IV patients received CT and/or RT with regimens similar to those for stage I/II patients. Results: Except for 1 patient with an initial surgical diagnosis, 56 patients underwent gastric endoscopic examination, which proved that 42 had NHL. The rate of diagnostic accuracy by gastroscopy was 75%. After multimodal treatment (n = 46) and a median follow-up of 54 months (range, 1-210 months), the 5-year survival rate was 40.3%. The 5-year survival rates for stage I, II and III/IV patients were 57.2%, 47% and 0%, respectively (p <0.005). Of the 24 surgical patients (group A) who received sequential CT, with or without RT, 12 remained disease-free after a median follow-up of 98 months (range, 1-210 months); three patients died because of postoperative complications. Of the 22 non-surgical patients (group B) who received CT, alone or combined with RT, 14 remained disease-free after a median follow-up of 40 months (range, 4-189 months); 1 patient died because of massive gastric hemorrhage after CT. All stage III and IV patients died after a median survival of 4 months (range, 1-8 months). Conclusion: Clinical stage is the most important factor predicting the long-term survival of patients with gastric NHL. Surgery may still be necessary in cases of failed gastroscopic diagnosis. In early-stage gastric NHL, non-surgical treatment seems able to achieve the aims of improved long-term survival and, in some instances, cure.

KW - Chemotherapy

KW - Gastroscopy

KW - Non-Hodgkin's lymphoma

KW - Radiotherapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=13544252738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13544252738&partnerID=8YFLogxK

M3 - Article

C2 - 15742857

AN - SCOPUS:13544252738

VL - 68

SP - 11

EP - 15

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 1

ER -